U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257055) titled 'Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study' on Nov. 21.
Brief Summary: to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Study Start Date: May 12, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 2 Study
MCL
BTKi
Rituximab
Glofitamab
Intervention:
DRUG: Acalabrutinib
Given by po
DRUG: Rituximab
Given by IV
DRUG: Glofitamab
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....